Mirum Pharmaceuticals' muted future revenue growth compared ...
Mirum Pharmaceuticals' muted future revenue growth compared to broader industry may struggle to support its current P/S ratio. The modest growth could potentially drag down shares despite maintaining current prices.
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business Is Yet to Catch Up With Its Share Price
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment